新冠疫苗有效性:2021年8月突尼斯检测阴性病例对照研究
该研究在2021年8月2日至15日对60岁以上人群开展匹配病例对照研究,纳入977名按年龄和性别匹配的受试者,评估新冠疫苗有效性。总体疫苗有效性为70%[95%CI 62.8-75.8%],预防重症和死亡的有效性分别为86.6%和98.4%(完全接种方案)。结论认为突尼斯使用的新冠疫苗可有效预防SARS-CoV-2感染及重症。
要点
- 总体疫苗有效性为70%[95%CI 62.8-75.8%],男性和女性分别为73%和67%。
- 预防有症状和无症状感染的有效性为77.6%[95%CI 70.9-82.8%]。
- 完全接种方案预防重症有效性86.6%,预防死亡有效性98.4%。
核心结论
- 突尼斯使用的新冠疫苗可有效预防SARS-CoV-2感染及重症,为疫苗持续使用决策提供真实世界数据。
研究设计与样本
- 2021年8月2日至15日开展的匹配病例对照研究,病例和对照为60岁以上人群,选自国家检测数据库,按年龄和性别匹配,共纳入977名受试者。
主要发现
- 总体疫苗有效性为70%[95%CI 62.8-75.8%]。
- 男性疫苗接种率68.1%,疫苗有效性73%[95%CI 62.9-80.3%];女性疫苗接种率56.4%,疫苗有效性67%[95%CI 55.8-75.3%],不分疫苗方案完整与否。
- 60-70岁年龄组疫苗有效性较高,为72.3%[95%CI 62.8-79.3%]。
- 预防有症状和无症状感染的有效性为77.6%[95%CI 70.9-82.8%]。
- 完全接种方案预防重症(需氧疗或入住ICU)的有效性为86.6%[95%CI 75.6-92.7%],预防COVID-19死亡的有效性为98.4%[95%CI 79.2-99.8%]。
临床怎么用
- 原文结论认为研究结果可指导疫苗持续使用的决策,未给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In response to the COVID-19 pandemic, multiple vaccines to protect against COVID-19 disease have been developed rapidly. Precise estimates of vaccine effectiveness (VE) vary according to studies design, outcomes measured and circulating variants. The aim of this study was to evaluate the anti-covid-19 vaccine effectiveness in Tunisia. METHODS: We conducted a matched case-control study from 2nd to 15th August 2021. Cases and controls were subjects over 60 years of age, selected from the National testing database, regardless vaccine status. A standardized questionnaire was administered for cases and controls to collect information about vaccination status. For cases, vaccination status was defined based on the number of doses received before becoming ill and excludes doses received during the previous two weeks. For matched controls, a reference date based on the case's date of illness onset was defined in order to look at the control's vaccination status before its corresponding case became ill. The odds-ratio was calculated using simple conditional logistic regression. The VE (95 % confidence intervals) was calculated as (1 - odds ratio for vaccination) × 100 %. RESULTS: A sample of 977 matched peers for age and Gender, were included between August 2, and August 15, 2021. The overall vaccine effectiveness (VE) was 70 % [95 % CI 62.8-75.8 %]. Among our sample, 68.1 % of the male population and 56.4 % of the female population were vaccinated with a VE of 73 % [95 % CI 62.9-80.3 %] and 67 % [95 % CI 55.8-75.3 %] respectively, regardless vaccine scheme (complete or incomplete). VE was higher for the age group [60-70 years[ (72.3 % [95 % CI 62.8-79.3 %]). VE was 77.6 % [95 % CI 70.9-82.8 %] to prevent both symptomatic and asymptomatic forms of the disease. Moreover, in prevention from severe forms (treated with oxygen-therapy or admission to an Intensive-care-unit) VE was 86.6 % [95 % CI 75.6-92.7 %] and 98.4 % [95 % CI [79.2-99.8 %] in prevention from COVID-19 deaths with a complete anti-Covid vaccination scheme. CONCLUSION: The results of our study showed that the anti-Covid-19 vaccines used in Tunisia are efficient to prevent both SARS-COV-2 infections and severe forms related to the disease. This study provided important data on the performance of vaccines in real-world settings that guide decisions about vaccine sustained use.
引用
- Mziou E, Hchaichi A, Letaief H, et al. Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021. Vaccine. 2024. PMID: 38365483. doi:10.1016/j.vaccine.2024.02.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。